Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by CROSSJECT
Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe
May 02, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject reports audited financial results for 2023
April 25, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject advances in its U.S. Strategy and reports Financial Results for 2023
April 02, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject gender equality score reaches 96/100 in 2024
March 08, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject obtains a financing up to €12 million, in two tranches
February 27, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject provides strategic update on priorities for 2024
February 06, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET
February 01, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject to present at Biotech Showcase on January 9 at 16:30 PT
January 09, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
January 04, 2024
From
CROSSJECT
Via
GlobeNewswire
Crossject signs ZEPIZURE® commercialization agreement for northern Europe
December 22, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject announces initiation of coverage by ODDO BHF
November 28, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject reports financial results and business highlights for first half of 2023
September 26, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject announces significant improvement in Gaïa ESG rating
September 11, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures
September 05, 2023
From
CROSSJECT
Via
GlobeNewswire
Crossject signs new licensing agreement on ZENEO® Midazolam epilepsy rescue therapy with AFT Pharmaceuticals for Australia & New Zealand
July 20, 2023
From
CROSSJECT
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.